SCI
NBIX icon

S&CO Inc’s Neurocrine Biosciences NBIX Stock Holding History

S&CO Inc’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18M Hold
7,000
– – 0.07% 136
2026
Q1 		$922K Hold
7,000
– – 0.06% 143
2025
Q4 		$992K Hold
7,000
– – 0.06% 141
2025
Q3 		$982K Hold
7,000
– – 0.06% 146
2025
Q2 		$879K Buy
7,000
+2,000
+40% +$229K 0.06% 148
2025
Q1 		$553K Hold
5,000
– – 0.04% 169
2024
Q4 		$682K Hold
5,000
– – 0.05% 158
2024
Q3 		$576K Hold
5,000
– – 0.04% 171
2024
Q2 		$688K Hold
5,000
– – 0.05% 162
2024
Q1 		$689K Buy
+5,000
New +$683K 0.05% 158

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

S&CO Inc's NBIX Position: Q2 2026 in Review

S&CO Inc held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 7,000 shares worth $1.18M. The position accounts for 0.07% of the portfolio, ranked #136.

S&CO Inc first reported a position in NBIX in Q1 2024 and has held it in 10 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • S&CO Inc held 7,000 shares of Neurocrine Biosciences worth $1.18M as of Q2 2026.
  • S&CO Inc left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up 0.07% of S&CO Inc's portfolio in Q2 2026, its #136 holding.
  • S&CO Inc first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 10 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on S&CO Inc's 13F filing for Q2 2026, filed 6 Aug 2026.